Pricing varies depending on coverage, with commercially insured patients potentially paying as little as $25 per month with savings programs, while self-pay options start at around $149 monthly for lower doses
MartinezFde AndradeJAnstromKKingTRaghuG
So by 2029, this firm global data says a total of five drugs will be monopolizing the GLP-1 market with 83% of sales
There is no medically established human dose for Dihexa
The one human trial that will measure tolerability directly has not started reporting it is only recruiting (planned 2026), studies a topical gel on small standardized wounds , and lists safety as a secondary, not primary, outcome (NCT07437586)
Their prescribing protocol, monitoring targets, and likely co-prescriptions are different